The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The emergence of the omicron COVID-19 variant is encouraging many already vaccinated adults to get a recommended booster shot but is providing only a little motivation for unvaccinated adults to get an initial shot, a new KFF COVID-19 Vaccine Monitor quick response survey finds. Fielded from Dec.
This analysis from the KFF COVID-19 Vaccine Monitor explores the public's response to the news about the omicron variant of coronavirus, and finds that while it may convince vaccinated adults to get their COVID-19 booster vaccine, unvaccinated adults are largely unmoved by the news.
The partisan divide that has emerged early into America’s booster campaign could increase pressure on health systems in heavily Republican areas if booster intentions hold.
A new KFF COVID-19 Vaccine Monitor analysis finds that Republicans and Republican leaning independents, who represent 41% of adults, now make up 60% of the adult unvaccinated population across the country and that political partisanship is a stronger predictor of whether someone is vaccinated than any demographic factor measured.
This analysis shows that as COVID-19 vaccination rates have increased over time, Republicans make up an increasingly disproportionate share of those who remain unvaccinated and that political partisanship is a stronger predictor of whether someone is vaccinated than demographic factors such as age, race, level of education, or insurance status.
This report finds the public is generally supportive of U.S. distribution of vaccines internationally, though more likely to prefer the U.S. playing a major role versus a leading one, and there are partisan differences. The analysis also examines how different information affects the public's views.
In this column for the JAMA Health Forum, Larry Levitt explores why the Medicaid "coverage gap" still exists in 12 states that have not expanded their Medicaid programs under the Affordable Care Act, why it matters, and why eliminating it could prove challenging.
In this Axios column, Drew Altman examines the lessons for COVID-19 as a political issue from Governor Gavin Newsom's resounding win in California’s recall election.
This post examines a growing COVID-19 vaccine gap in Red and Blue America, with the share of the population that have been fully vaccinated in counties that voted for President Biden in 2020 increasing more rapidly than the share in counties that voted for President Trump.
In response to prescription drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing the federal government to negotiate the price of prescription drugs for Medicare and private payers. This brief describes the current status of drug price negotiation proposals, looks back at the history of proposals to give the federal government the authority to negotiate drug prices in Medicare, describes the negotiation provisions in key legislation (H.R. 3), and discusses the potential spending effects for the federal government, beneficiaries, and private payers.
© 2026 KFF